TargetMol

6-Mercaptopurine hydrate

Product Code:
 
TAR-T2201
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T2201-1mL1 mL * 10 mM (in DMSO)£95.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2201-25mg25mg£101.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2201-50mg50mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2201-100mg100mg£120.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2201-500mg500mg£136.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
6-Mercaptopurine anhydrous is a Nucleoside Metabolic Inhibitor. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
CAS:
6112-76-1
Formula:
C5H6N4OS
Molecular Weight:
170.19
Pathway:
DNA Damage/DNA Repair; Cell Cycle/Checkpoint;
Purity:
0.9992
SMILES:
O.S=c1[nH]cnc2nc[nH]c12
Target:
Nucleoside Antimetabolite/Analog; DNA/RNA Synthesis

References

1. Sahasranaman S, et al. Eur J Clin Pharmacol, 2008, 64(8), 753-767. 2. Weinshilboum RM, et al. Am J Hum Genet, 1980, 32(5), 651-662. 3. Fu Y H, Xu Z X, Jiang N, et al. High-throughput screening of active compounds against human respiratory syncytial virus. Virology. 2019.